Nonalcoholic Steatohepatitis Treatment Market Report Explored in Latest Research to 2026

Nonalcoholic
Steatohepatitis
Treatment
Market Size, Share, Trend, Outlook, Future
Growth Analysis And Synthesis 2018 - 2026
Nonalcoholic steatohepatitis (NASH) is a form of nonalcoholic fatty liver disease (NAFLD) in which a
person have hepatitis and inflammation of the liver, and can cause liver damage. NASH can lead to
complications, such as cirrhosis and liver cancer. Patients with NASH have high chance of mortality due
to liver-related causes such as liver failure.
Lifestyle modification, including change in diet and exercise, is the basic therapy recommended for
nonalcoholic fatty liver disease. However, in some cases lifestyle modification is difficult to achieve and
to sustain, and therefore required other treatments including medicine.
Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/2279
Currently available drugs for the treatment of NAFLD were historically been given for other indications.
For instance, Orlistat, a gut lipase inhibitor, is indicated for decrease in the dietary fats absorption.
According to the National Center for Biotechnology Information (NCBI) 2017 study, Orlistat has been
approved for treatment of obesity and is available over the counter in the U.S. for weight loss. Orlistatmediated weight loss is related with reduction in hepatic steatosis.
The global nonalcoholic steatohepatitis treatment market size was valued at US$ 1,119.9 million in 2017
(based on existing approved therapies anti-diabetics, vitamins, dietary supplements, and others) and is
expected to witness a CAGR of 42.7% over the forecast period (2018 – 2026).
Rising incidence of nonalcoholic steatohepatitis and strong product pipeline are expected to drive the
nonalcoholic steatohepatitis treatment market revenue
Nonalcoholic steatohepatitis has become one of the most common liver-related health problems. The
condition has been linked to an unhealthy diet and weight gain, but it can also be observed in nonobese individuals. Increasing prevalence of insulin resistance, and obesity is expected to fuel the
nonalcoholic steatohepatitis treatment market during the forecast period.
According to an article published in Lancet, globally, prevalence of overweight and obesity combined
has risen by 27.5% for adults between 1980 and 2013. According to the National Health and Nutrition
Examination Survey (NHANES) 2014 data, in U.S. the percentage of obesity is higher in women, i.e.
40%, than in men, 35%.
Get Full Access of This Business Report:
https://www.coherentmarketinsights.com/market-insight/nonalcoholic-steatohepatitis-treatment-market-2279
Nonalcoholic Steatohepatitis Treatment Market - Regional Insights
On the basis of region, the global nonalcoholic steatohepatitis treatment market is segmented into North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America and Europe
nonalcoholic steatohepatitis treatment market is expected to foresee significant growth owing to
increasing incidence of obesity and fatty liver.
Report includes chapters which deeply display the following deliverable about industry :
• Nonalcoholic Steatohepatitis Treatment Market Research Objective and Assumption
• Nonalcoholic Steatohepatitis Treatment Market Purview - Report Description, Executive
Summary, and Coherent Opportunity Map (COM)
• Nonalcoholic Steatohepatitis Treatment Market Dynamics, Regulations, and Trends Analysis Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Nonalcoholic Steatohepatitis Treatment Market, By Regions
• Nonalcoholic Steatohepatitis Treatment Market Competition by Manufacturers including
Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and
Product Type.
• Nonalcoholic Steatohepatitis Treatment Market Manufacturers Profiles/Analysis including
Company Basic Information, Manufacturing Base and Its Competitors.
• Nonalcoholic Steatohepatitis Treatment Market Manufacturing Cost Analysis including Key Raw
Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Nonalcoholic Steatohepatitis Treatment Market Forecast including Production, Consumption,
Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Nonalcoholic Steatohepatitis Treatment Market - Competitive Landscape
Key players operating in the global nonalcoholic steatohepatitis treatment market include AstraZeneca
Plc., Conatus Pharmaceuticals, Enzo Biochem, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Gilead
Science, Immuron Ltd., Intercepts Pharmaceuticals, Novo Nordisk, Raptor Pharmaceutical Corporation,
and Tobira Therapeutics, Inc.
Detailed Segmentation:
Global Nonalcoholic Steatohepatitis Treatment Market, By Drug:
•
Cenicriviroc
•
Elafibranor
•
Ocaliva (Obeticholic Acid)
•
Selonsertib
Global Nonalcoholic Steatohepatitis Treatment Market, By Distribution Channel:
•
Hospital Pharmacy
•
Retail Pharmacy
•
Online Pharmacy
To Get Instant Access, Purchase Report Here:
https://www.coherentmarketinsights.com/insight/buy-now/2279
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

The global nonalcoholic steatohepatitis treatment market size was valued at US$ 1,119.9 million in 2017 and is expected to witness a CAGR of 42.7% over the forecast period (2018 – 2026).